Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)

This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural/intraperitoneal infusion of WSK-IM02 in patients with advanced solid tumors complicated by malignant pleural or peritoneal effusions who have failed standard of care.

Participants needed: 9
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: WestVac Biopharma Co., Ltd.Updated: May 29, 2026Locations: 1
Eligibility criteria

Age ≥18 years and ≤75 years. [+8]

Participation in any other interventional clinical trial within 4 weeks prior to... [+18]

Status: Not yet recruiting

A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.

A Phase 1, single-arm, single-center, open-label, prospective, dose-escalation, and cohort expansion study to assess the safety, tolerability, pharmacokinetic (PK), and preliminary efficacy of WSK-IM02 administered as a single agent to patients with platinum-resistant recurrent ovarian cancer.

Participants needed: 36
Trial details
Phase: Phase 1Age: 18-75Biological sex: FemaleType: InterventionalSponsor: WestVac Biopharma Co., Ltd.Updated: Mar 13, 2026
Eligibility criteria

Female, age ≥18 years old, ≤ 75 years old. [+8]

Participation in another investigational drug trial within 4 weeks before enroll... [+24]

Status: Recruiting

A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.

Participants needed: 60
Trial details
Phase: Phase 2Age: 14+Biological sex: AllType: InterventionalSponsor: WestVac Biopharma Co., Ltd.Updated: Jan 30, 2026Locations: 7
Eligibility criteria

Age: 14 years through 65 years of age, male or female [+6]

Those who cannot take delamanid, bedaquiline, or linezolid for various reasons [+34]

Status: Not yet recruiting

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, Safety and Immunogenicity

Participants needed: 4,950
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: WestVac Biopharma Co., Ltd.Updated: Jul 25, 2024
Eligibility criteria

Subjects aged 18 years and above, including those with underlying diseases and i... [+3]

Axillary temperature ≥37.3℃. [+17]

Status: Not yet recruiting

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination to evaluate safety and immunogenicity in healthy population aged 18 years old and above.

Participants needed: 3,100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: WestVac Biopharma Co., Ltd.Updated: Jul 25, 2024
Eligibility criteria

Subjects aged 18 years and above, including those with underlying diseases and i... [+3]

Axillary temperature ≥37.3℃. [+17]